News » Money
Apr 15, 5:01 PM EDT

Charles Schwab, MasterCard, PetSmart, Halozyme and Coca-Cola are big market movers

Business Video

Buy AP Photo Reprints
Greece's Debt Threatens to Spread
State budget
gaps map
Auto industry problems trickle down, punish Tennessee county
Women give old Derby hats a makeover in tough economy
S.C. town deals with highest unemployment in South
How mortgages were bundled and sold as securities
Tracking the $700 billion financial bailout
Tracking the year's job losses
State-by-state foreclosures since 2007
Credit crisis explained
Presidents and their economic legacies
Lexicon of the financial crisis
Americans' addiction to debt
Are Stocks Bouncing Back?

NEW YORK (AP) -- Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:


The Coca-Cola Co., up $1.45 to $40.18

The first global sales volume decline for soda in at least a decade was offset by sales of noncarbonated drinks such as juice.

MasterCard Inc., up 97 cents to $72.15

Janney Capital upgraded major credit card companies citing a significant pullback in stock prices and solid business plans.

Johnson & Johnson, up $2.06 to $99.20

Controlled costs and a jump in prescription drug sales fueled an 8 percent increase in quarterly profit at the health care company.

Whirlpool Corp., up $3.09 to $151.46

Bonuses for shareholders as the appliance maker announces a new $500 million share repurchase program and a bigger dividend.

The Charles Schwab Corp., up 81 cents to $26.11

Profit rose almost 60 percent with the broker picking up healthy asset-management fees and saw stronger trading revenue.


PetSmart Inc., down $2.76 to $66.61

New competition in pet care will create some headwinds, according to Bank of America Merrill Lynch, which downgraded the retailer.

Zebra Technologies Corp., down $6.89 to $61.39

The bar-code company will spend $3 billion to buy the enterprise business of Motorola Solutions in a considerable expansion.

Halozyme Therapeutics Inc., up 20 cents to $7.39

Citigroup initiated coverage of the biopharmaceutical company, saying Wall Street is not recognizing its value when compared to peers.

© 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.